Cosmo Bio Co

Cosmo Bio Co Acquisitions (Net)

The Acquisitions (Net) of Cosmo Bio Co (3386.T) as of Oct 29, 2026 is 324.00 M JPY. In the previous year, Acquisitions (Net) was 59.00 M JPY — a change of 449.15% (higher).

Acquisitions (Net)

324.00 MJPY

YoY

449.15%

Last updated:

Acquisitions (Net) of Cosmo Bio Co is 2025 324.00 M JPY. Acquisitions (Net) of Cosmo Bio Co was 2024 59.00 M JPY. It decreases by 449.15% higher compared to the previous year.

The Cosmo Bio Co Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
-33.00 M JPY
Jan 1, 2019
67.00 M JPY
Jan 1, 2020
107.00 M JPY
Jan 1, 2021
-4.00 M JPY
Jan 1, 2022
-187.00 M JPY
Jan 1, 2023
-658.00 M JPY
Jan 1, 2024
59.00 M JPY
Jan 1, 2025
324.00 M JPY
The Cosmo Bio Co Acquisitions (Net) history
YEARAcquisitions (Net)YoY
324.00 MJPY+449.15%
59.00 MJPY-108.97%
-658.00 MJPY+251.87%
-187.00 MJPY+4,575.00%
-4.00 MJPY-103.74%
107.00 MJPY+59.70%
67.00 MJPY-303.03%
-33.00 MJPY-110.61%
311.00 MJPY-11.40%
351.00 MJPY-648.44%
-64.00 MJPY-45.76%
-118.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Acquisitions (Net) of Cosmo Bio Co is 324.00 M JPY in 2025.

Acquisitions (Net) of Cosmo Bio Co changed from 59.00 M JPY to 324.00 M JPY, representing a 449.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co